Kornimate/medical-research-clean huggingface dataset:
effects of gluten-free diet on nutritional status in celiac patients

Conditions: Celiac Disease

Summary: this study examined the impact of a gluten-free diet on nutritional status and inflammation markers in adult celiac patients compared to a control group. twenty-six celiac patients and 26 healthy individuals participated. interviews, dietary records, anthropometric measurements, and blood samples were collected. after six weeks, celiac patients showed improved adherence to the gluten-free diet and increased quality of life scores. while initial micronutrient intake was lower in celiac patients, it improved over the study period. however, there were no significant changes in inflammation markers.

this study aimed to examine the effects of a gluten-free diet on the nutritional status, anthropometric measurements, and serum levels of interferon-gamma (ifn-γ) and interleukin-15 (il-15) in adult celiac patients, comparing them with a control group. a total of 26 celiac patients aged 18-64 years and 26 healthy individuals as the control group were included. face-to-face interviews were conducted to determine participants\&#39; general characteristics, dietary habits, and physical activity status. additionally, a retrospective 24-hour dietary recall and food frequency questionnaire were administered to assess dietary intake. anthropometric measurements and blood samples were collected during the interviews. celiac patients received education about the gluten-free diet, and follow-up assessments were conducted six weeks later. at the beginning, 53.8% of celiac patients reported always/mostly adhering to the gluten-free diet, which increased to 100.0% after six weeks. the total quality of life scores significantly increased in celiac patients after six weeks. initial serum il-15 levels were similar between celiac and control groups, whereas serum ifn-γ levels were significantly higher in celiac patients compared to the control group.

Eligibility criteria:
inclusion criteria: * adults aged between 19 and 64 years old. * diagnosis of celiac disease. * willingness to participate in the study. * ability to adhere to the study protocol, including dietary restrictions and follow-up assessments. * for the control group, individuals without celiac disease or any other significant health conditions. exclusion criteria: * individuals following diets other than a gluten-free diet. * individuals adhering to a gluten-free diet for reasons other than celiac disease. * individuals with gastrointestinal diseases other than celiac disease. * individuals who have undergone gastrointestinal surgery. * individuals with mental illnesses. * cancer patients. * individuals positive for hepatitis b surface antigen or anti-hepatitis c virus antibody. * individuals using interferon and/or insulin. * pregnant or lactating women.

Keywords: celiac disease inflammation interferon-gamma interleukin-15
ct c-spine audit and feedback

Conditions: Cervical Spine Injury; Emergencies; Trauma

Summary: this is a prospective quality improvement study to assess the effect of using an audit-and-feedback process for emergency providers on utilization of computed tomography of the cervical spine. the objective of this study is to determine whether providing repeated individualized feedback on ct c-spine utilization to emergency providers alters their practice pattern and reduces overutilization. the investigators hypothesize that emergency providers who receive individualized feedback regarding their ct c-spine utilization on a regular basis will alter their practice pattern to reduce overutilization of this imaging study.


Eligibility criteria:
inclusion criteria: * emergency medicine physician, nurse practitioner, or physician assistant * ordered at least 5 ct scans of the cervical spine on adult patients in the two-month pre-intervention period exclusion criteria: * non-emergency providers * ordered few than 5 studies in the pre-intervention period

Keywords: computed tomography resource utilization nexus emergency medicine
follow-up of actual patient care site two months after hospitalisation compared with their expressed choice regarding subsequent care site (respect)

Conditions: Hematologic Malignancy; Tumor, Solid

Summary: this is a non randomized, monocentric, descriptive, transversal and prospective study. the purpose of this study is to assess the compliance with patient expressed choice regarding subsequent care and death -if occured- site (at hospital or at home) after hospitalisation for terminally ill patients with an onco-hematologic solid tumor in palliative care and to identify reasons for potential non-compliance.

patients will reply to two questionnaires, at inclusion and two months after inclusion. primary care physician will also be contacted by phone to reply to two questionnaires, at inclusion and two months after inclusion.

Eligibility criteria:
inclusion criteria: * patients must be ≥ 18 years old * patients with onco-hematologic solid tumor (locally advanced or metastatic) against which specific and systemic treatments are outdated or have been stopped (symptomatic palliation with radiotherapy is allowed) * patients admitted in full hospitalisation * patients able to speak, read and understand french * patients able to answer the phone * signed informed consent from the patient * patients must have a social security coverage exclusion criteria: * patients \< 18 years old or incapable person ≥ 18 years old * patients admitted for any surgical intervention * patients unable to read french * patients whose physical or psychological condition do not allow them to answer orally or in writing * patients deprived of liberty * patients placed under judicial protection * women that are pregnant or breast-feeding
azd8848 single ascending dose study

Conditions: Healthy

Summary: this study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of azd8848 in healthy subjects.

a double-blind, placebo-controlled, randomised study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending inhaled doses of azd8848 in healthy subjects

Eligibility criteria:
inclusion criteria: * healthy men or women aged 18 to 45 years (inclusive) with suitable veins for cannulation or repeated venipuncture. * women can be of childbearing potential and must have been stable on a highly effective contraceptive method for at least 3 months prior to visit 1 (screening) and be willing to continue on the chosen contraceptive method * male subjects should be willing to use a condom (with spermicide) to prevent pregnancy and drug exposure of a female partner and refrain from donating sperm or fathering a child from the day of the investigational product administration until 3 months * have a body mass index (bmi) between 18 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg * ability to produce sputum of good enough quality for assessment of biomarkers exclusion criteria: * abnormal vital signs, after 10 minutes supine rest, defined as any of the following (sbp \> 140 mmhg, diastolic blood pressure (dbp) \> 90 mmhg, heart rate \ 85 beats per minute) * prolonged qtcf \> 450 ms or shortened qtcf \< 340 ms or family history of long qt syndrome * history of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class as azd8848 * history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalaemia, family history of long qt syndrome, or sudden death) * history of asthma or allergic rhinitis

Keywords: safety tolerability healthy pharmacokinetic pharmacodynamic inhaled
optimizing navigation to successful colorectal cancer screening

Conditions: Colorectal Cancer Screening

Summary: colorectal cancer is the second leading cause of death from cancer in the united states. two major barriers to successful colorectal cancer screening are appointment keeping and proper bowel preparation. the purpose of this study is to test the efficacy of a patient navigation program to increase colorectal cancer screening at rush university medical center. the investigators hypothesize that colorectal cancer screening will be improved for subjects who utilize a patient navigator.


Eligibility criteria:
inclusion criteria: * subject deemed appropriate for colorectal cancer screening by colonoscopy by a primary care physician * age 50 or greater or 40 or greater with family history of colorectal cancer in first degree relative * average risk for screening as defined as absence of symptomatic abdominal pain and active gi bleeding exclusion criteria: * age \> 75 years old * congestive heart failure * chronic obstructive pulmonary disease * myocardial infarction * weight greater than 350 pounds * anticoagulation * inability to speak english

Keywords: colonoscopy colon cancer screening navigation
a multi-center, longitudinal, observational study of children with achondroplasia

Conditions: Achondroplasia

Summary: this is a long-term, multi-center, longitudinal, observational study in children with achondroplasia (ach). the aim is to study height velocity and comorbidities in children with ach. this is a natural history study and no study medication will be administered.


Eligibility criteria:
inclusion criteria: 1. legally authorized representative is willing and able to provide written, signed informed consent (with a written assent from the child when appropriate per local requirements) 2. willing and able to comply with study protocol per investigator judgement 3. clinical diagnosis of achondroplasia (confirmed by the investigator) 4. age between 0 to 8 years old at enrollment 5. able to stand without assistance (if the child is 24 months or older) exclusion criteria: 1. have received chronic treatment (\> 3 months) of human growth hormone (hgh) or other medicinal products intended to affect stature or body proportionality at any time 2. have received any dose of medicinal products intended to affect stature or body proportionality within the previous 6 months of screening 3. have received any investigational medicinal product or device intended to affect stature or body proportionality at any time 4. history or presence of injury or disease of the growth plate(s), other than ach, that affects growth potential of long bones 5. history of any bone-related surgery that affects growth potential of long bones, such as orthopedic reconstructive surgery and osteotomy (foramen magnum decompression, and laminectomy with full recovery are allowed with minimum of 6 months of bone healing. limb-lengthening with full recovery is allowed with a minimum of 12 months of bone healing.) 6. have forms of skeletal dysplasias other than achondroplasia or medical conditions that result in short stature or abnormal bone growth \[such as severe achondroplasia with developmental delay and acanthosis nigricans (saddan), hypochondroplasia, growth hormone deficiency, turner syndrome, pseudoachondroplasia. uncontrolled hypothyroidism, uncontrolled diabetes mellitus, autoimmune disease requiring corticosteroid therapy, inflammatory bowel disease, and chronic renal insufficiency\] 7. history or presence of malignant disease, other than basal cell epithelioma/carcinoma or completely resected squamous skin cancer with no recurrence for 12 months per medical records

Keywords: achondroplasia dwarfism
spectalung: screening patients with thoracic tumors for efficient clinical trial access

Conditions: Any Stage of Lung Cancer (Any Histotype); Any Stage of Malignant Pleural Mesothelioma; Any Stage of Any Thymic Malignancy

Summary: spectalung is a program aiming at screening patients with thoracic tumors to identify the molecular characteristics of their disease. the thoracic tumors include lung cancer, malignant pleural mesothelioma, thymoma or thymic carcinoma at any stage. once the molecular characteristics are identified, there might be the possibility to offer these patients access to targeted clinical trials.


Eligibility criteria:
inclusion criteria: * pathologically confirmed lung cancer, mpm, thymoma or thymic carcinoma at any stage; * mandatory availability of adequate human biological material (hbm): ffpe tissue sample from the primary tumor, recurrent tumor, metastasis, obtained at the time of primary surgery or biopsy; minimal amount requested is detailed in the hbm guidelines; inclusion of samples taken at any recurrence diagnosed during follow-up is strongly encouraged but optional; * centrally performed confirmation of tumor tissue adequacy in terms of quality/ quantity for central screening; * age ≥ 18 years; * at least three months life-expectancy; * written informed consent according to ich/gcp and national/local regulations. exclusion criteria: * any active malignancy, except pt1-2 prostatic cancer gleason score \< 6, non melanomatous skin cancer or carcinoma in situ of the cervix, in the 5 years before study entry; * active hepatitis b/c or hiv; * any secondary malignancy; * any severe organ dysfunction or other comorbidities that may prevent the inclusion into clinical trials.

Keywords: lung cancer malignant pleural mesothelioma thymic malignancy biomarkers screening
short and long-term psychological impact of covid-19 on the egyptians

Conditions: Mental Health Issue

Summary: the world health organization (who) has recently declared coronavirus disease 2019 (covid-19) a public health emergency of international concern. impact of the pandemic of covid-19 on the mental health of patients, health care workers and general population would be affected.

health care workers and general population will be included in the study. a questionnaire will be used to assess their knowledge and practices regarding covid-19 and its impact on mental health. patients mental health will be assessed regarding anxiety, depression and obsessive compulsive disorder, sleep disorder will be assessed.

Eligibility criteria:
inclusion criteria: * egyptian population exclusion criteria: * patients not accepting to participate in the questionnaire

Keywords: covid-19 egyptian health workers population mental health
covid-19 antibody levels after vaccines

Conditions: Vaccine Preventable Disease

Summary: this study will measure the levels of nasal mucosal immunoglobulin a (iga) and blood serum iga up to one year after covid vaccination, as well as examining what factors might affect antibody levels in the nose. this will be done through nasal epithelial lining fluid collection and standard venipuncture.

based on data demonstrating that sars-cov-2 infections results in virus-specific nasal iga levels even in patients with mild infections and no/low serum antibody titers, we hypothesize that covid vaccinations result in robust nasal iga levels. since previous data indicate that sars-cov2 specific iga were transiently present following community-acquired infections, we will follow vaccine-induced nasal iga levels over time (6-12 months). our specific aims are as following: aim 1: determine covid vaccine specific immunoglobulin levels and immune mediator profiles in the nasal mucosa pre- and 14 days post second dose of covid vaccine. aim 2: determine covid specific immunoglobulin levels and immune mediator profiles at 3, 6, and 12 months following complete vaccination.

Eligibility criteria:
inclusion criteria: * individuals at least 18 years of age who have or plan to receive a covid-19 vaccination * able to be seen at unc chapel hill's main campus up to 5 times in the next year exclusion criteria: * individuals unwilling to give consent

Keywords: covid-19 vaccination
photobiomodulation home-use device for prevention or treatment of oral mucositis in patients with head&neck malignancies

Conditions: Mucositis; Head and Neck Cancer; Radiotherapy Side Effect

Summary: patients with head and neck malignancy that are treated with radiation therapy \[rt\] are expected to develop oral mucositis (om) in 60% of cases. mucositis is a side effect of radiation and / or chemotherapy that causes severe pain and inability to eat and drink and a decrease in quality of life. in addition it may impair the treatment protocol and treatment outcomes. photobiomodulation is a non-ionizing optical radiation in the near or near-infrared range used for acceleration of wound healing and pain reduction. photobiomodulation therapy for the reduction of mucositis is included in the international guidelines of the mascc / isoo association and the british nice. to date the treatment has been performed by members of professional medical staff in hospitals or clinics. the study device is home-used photobiomodulation device approved for indications of pain reduction and acceleration of wound healing. the device has shown efficacy in treating mucositis around dental implants in a clinical trial and after oncological treatments in a limited number of cases as reported in the scientific literature.


Eligibility criteria:
inclusion criteria: 1. patients with malignant neoplasm in the oral cavity, pharynx or salivary glands. 2. the patient should receive a continuous course of radiation therapy (imrt) with all of the following criteria applicable: * for a period of 3-7 weeks, 5-6 fractions per week. * a minimum cumulative dose of 30gy expected to cause om (oral mucositis) by the third week. or: based on the clinical judgment of the radiation oncologist and bed2 ≥ 30 gy * the treatment field will include at least one oral site (buccal mucosa, floor of mouth, tongue, hard palate, retro-molar trigon, lips or oropharynx) * with or without chemotherapy and / or immunotherapy at the same time. 3. a patient with an ecog ps functional status equal to or less than 2 4. able to read and understand the informed consent form (icf) and voluntarily provided informed consent 5. the patient is able to undergo intra-oral treatments 6. the patient is willing to perform the protocol. exclusion criteria: 1. the patient underwent previous radiation to the current therapeutic field 2. the patient has health conditions of the teeth or mouth that will prevent the application of intra-oral treatment 3. the patient receives non-standard treatment for mucositis such as benzidamine, palifermin, etc. 4. the patient is enrolled to any other clinical trial that includes treatment or intervention that may affect the course of mucositis. 5. the patient has a diagnosis that affects the healing of wounds (eg diabetes, lupus, etc.) 6. pregnancy
asia down syndrome acute lymphoblastic leukemia 2016

Conditions: Down Syndrome; Acute Lymphoblastic Leukemia; Childhood Cancer

Summary: to evaluate the outcome of a prednisolone and low dose methotrexate based protocol in down syndrome children with all (ds-all) in an asia-wide study. the treatment protocol was modified based upon backbone of taiwan pediatric oncology group (tpog)-all protocol in which risk classification will be guided by level of flow minimal residual disease (mrd) instead.


Eligibility criteria:
inclusion criteria: * down syndrome diagnosed clinically or cytogenetically (including mosaic down) * newly diagnosed all according to who 2016 classification. * age \< 21 years old at time of enrollment. * ecog performance status (ps) score of 0-2. * written informed consent obtained from legally acceptable representatives. exclusion criteria: * second malignancy. * philadelphia positive all. * mature b-all. * mixed phenotype acute leukemia. * any previous treatment with cytotoxic chemotherapy excluding treatment for tam or radiation therapy. patient pre-treated with short term steroid (\< 7 days of duration within last 1 month prior to treatment start) can be enrolled into this study. * renal dysfunction with creatinine \>2x upper limit of normal (uln). patients whose creatinine has improved to \<2x uln before treatment commencement can enrol subject to discretion of site pi. * liver dysfunction with direct bilirubin \> 5x uln. * any serious uncontrolled medical condition or impending end organ dysfunction that would impair the ability of the subject to receive protocol therapy, including: 1. history of coronary arterial disease, cardiomyopathy, heart failure, arrhythmia (other than sinus arrhythmia) or severe cardiac malformation which with residual abnormalities or requires further major corrective surgery within 2 years. 2. ongoing uncontrolled hypertension. 3. ongoing uncontrolled diabetes mellitus. 4. ongoing uncontrolled infection. 5. history of congenital or acquired immunodeficiency including hiv infection. 6. history of interstitial pneumonia, pulmonary fibrosis, bronchiectasis or severe pulmonary emphysema. 7. cns hemorrhage. 8. psychiatric disorder. 9. other concurrent active neoplasms. * pregnant or lactating women. * doubtful compliance or ability to complete study therapy due to financial, social, familial or geographic reason, or in the judgement of site investigator.
somatic mindfulness training for a healthy workforce: student pilot sample

Conditions: Occupational-based Secondary Trauma

Summary: this pilot study evaluates a somatic mindfulness training. reductions in mental and physical health correlates of secondary trauma are assessed using a pretest-posttest design.


Eligibility criteria:
inclusion criteria: * participant must be either employed or volunteering as a victim service provider, or enrolled at montana state university as an undergraduate student. exclusion criteria: * participant is under age 18.
exercise performance on ambient air vs. low-flow oxygen therapy in pulmonary vascular disease (pvd)

Conditions: Pulmonary Vascular Disorder; Chronic Thromboembolic Pulmonary Hypertension; Pulmonary Arterial Hypertension

Summary: the investigators aim to study the effect of sot in swiss residents with pulmonary vascular diseases (pvd) defined as pulmonary arterial hypertension (pah) or chronic thromboembolic pulmonary hypertension (cteph).

participants with pvd diagnosed with precapillary ph with right heart catheterization and classified to groups 1 and 4 (pah or cteph) who live in switzerland will have 6-minute walk distance (6mwd) test with and without sot approximately 3l/min via nasal cannula according to a randomized cross-over design. the trial aims to test that the 6mwd with sot is non-inferior to a 6mwd in the same participant under ambient air. the effect size was estimated with a difference of less or equal to 35m compared under sot compared to ambient air.

Eligibility criteria:
inclusion criteria: * minimum 18 years of age * written informed consent * patients with diagnosed pulmonary arterial hypertension (pah), distal chronic thromboembolic pulmonary hypertension (cteph) * former desaturation under exercise defined as spo2-decrease \>3% * treated with a stable drug therapy (with no changes for at least 14 days prior to screening) exclusion criteria: * severe hypoxemia needing supplemental oxygen therapy defined as partial pressure of o2 (pao2) \< 6.9 kilopascal (kpa) * pregnancy * unability or contraindications to undergo the investigated intervention * unability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc

Keywords: pulmonary hypertension supplemental oxygen therapy pulmonary arterial hypertension chronic thromboembolic pulmonary hypertension pulmonary vascular disease 6 minute walking distance